Aclaris Therapeutics Inc Stock Research

Market Summary

USD8.79+0.09

Market Closed

1.03%

ACRS Alerts

Big jump in Revenue (Y/Y)
Big fall in earnings (Y/Y)
Losses in recent quarter

ACRS Stock Price

ACRS RSI Chart

ACRS Valuation

Market Cap

590.7M

Price/Earnings (Trailing)

-6.14

Price/Sales (Trailing)

19.16

EV/EBITDA

-6.34

Price/Free Cashflow

-7.99

ACRS Price/Sales (Trailing)

ACRS Profitability

Operating Margin

86.48%

EBT Margin

-292.11%

Return on Equity

-43.98%

Return on Assets

-34.14%

Free Cashflow Yield

-12.52%

ACRS Fundamentals

ACRS Revenue

Revenue (TTM)

30.8M

Revenue Y/Y

73.98%

Revenue Q/Q

-67.39%

ACRS Earnings

Earnings (TTM)

-96.3M

Earnings Y/Y

-49.87%

Earnings Q/Q

-1.9%

Price Action

52 Week Range

5.7718.96

(Low)(High)

Last 7 days

6.0%

Last 30 days

-2.3%

Last 90 days

-31.2%

Trailing 12 Months

-39.3%

ACRS Financial Health

Current Ratio

10.55

ACRS Investor Care

Shares Dilution (1Y)

8.86%

Diluted EPS (TTM)

-1.44

Peers (Alternatives to Aclaris Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	409.0B	96.3B	-3.62%	-9.57%	32.14	4.25	1.46%	-35.83%
LLY	398.5B	27.7B	2.58%	47.15%	70.08	14.39	-5.56%	-7.22%
MRK	272.8B	57.9B	-4.82%	28.79%	17.88	4.63	7.21%	-8.11%
PFE	230.9B	93.0B	-0.23%	-25.99%	7.36	2.3	0.56%	16.36%
BMY	150.1B	45.8B	-1.47%	-11.26%	23.72	3.25	-2.37%	16.96%
MID-CAP
PRGO	5.0B	4.6B	-12.00%	-16.92%	-35.25	1.11	8.46%	-29.07%
RETA	3.5B	1.5M	-8.84%	225.36%	-11.32	1.6K	-86.94%	-16.59%
SMALL-CAP
SUPN	1.8B	668.5M	-9.91%	19.28%	34.95	2.72	11.17%	-29.04%
TLRY	1.6B	596.3M	-7.75%	-62.41%	-0.89	2.66	-3.41%	-3791.67%
INVA	866.9M	271.5M	14.22%	-13.24%	3.94	3.19	-31.50%	-40.28%
CRON	666.4M	112.3M	-6.91%	-41.08%	-4.29	5.94	7.69%	41.96%
ACRS	590.7M	30.8M	-2.33%	-39.30%	-6.14	19.16	378.90%	-19.01%
OCUL	536.4M	51.7M	11.79%	117.61%	-6.04	10.38	4.69%	-299.77%
CGC	401.1M	478.9M	-31.81%	-82.48%	-0.13	0.84	-31.50%	-634.70%
ENDP	94.1M	2.2B	-43.99%	-88.43%	-0.03	0.04	-25.47%	-292.77%

Financials for Aclaris Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	3.6%	30,827,000	29,752,000	23,500,000	6,141,000	6,437,000
S&GA Expenses	10.7%	27,824,000	25,133,000	24,930,000	25,096,000	24,891,000
R&D Expenses	10.6%	86,094,000	77,813,000	70,843,000	61,163,000	50,281,000
EBITDA	4.4%	-86,111,000	-90,063,000	-90,022,000	-	-
EBITDA Margin	80.3%	-2.89	-14.67	-13.99	-	-
Earnings Before Taxes	-	-86,908,000	-	-	-	-
EBT Margin	80.3%	-2.92	-14.80	-14.12	-	-
Net Income	-10.8%	-96,279,000	-86,908,000	-82,077,000	-83,271,000	-80,900,000
Net Income Margin	16.4%	-2.92	-3.49	-13.56	-12.57	-
Free Cahsflow	-2.9%	-68,172,000	-66,227,000	-68,922,000	-61,431,000	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-9.8%	230	255	268	278	227
Current Assets	-20.4%	184	232	257	259	191
Cash Equivalents	-1.2%	45.00	45.00	62.00	68.00	36.00
Net PPE	37.7%	2.00	1.00	1.00	1.00	1.00
Liabilities	-7.2%	53.00	57.00	48.00	42.00	46.00
Current Liabilities	-16.8%	18.00	22.00	20.00	16.00	17.00
Shareholder's Equity	-10.5%	177	198	220	236	180
Retained Earnings	-4.1%	-710	-682	-654	-634	-614
Additional Paid-In Capital	0.8%	888	881	876	872	795
Shares Outstanding	0.8%	67.00	67.00	67.00	67.00	62.00

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-8.0%	-72,951	-67,567	-65,527	-68,316	-60,871
Share Based Compensation	29.7%	19,499	15,039	14,077	13,591	13,731
Cashflow From Investing	-32.7%	8,494	12,628	750	-38,139	-62,386
Cashflow From Financing	0.1%	72,867	72,828	61,272	124,332	-

Risks for ACRS

What is the probability of a big loss on ACRS?

100%

Probability that Aclaris Therapeutics stock will be more than 20% underwater in next one year

100%

Probability that Aclaris Therapeutics stock will be more than 30% underwater in next one year.

91.2%

Probability that Aclaris Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ACRS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Aclaris Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for ACRS

Cumulative Returns on ACRS

-11.2%

7-Year Cumulative Returns

-13.6%

5-Year Cumulative Returns

81.9%

3-Year Cumulative Returns

What are the long-term rolling returns for ACRS?

FIve years rolling returns for Aclaris Therapeutics.

Annualized Returns

Which funds bought or sold ACRS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-26	ProShare Advisors LLC	reduced	-11.57	-118,866	98,925	-%
2023-05-22	AMERIPRISE FINANCIAL INC	reduced	-0.78	-560,613	581,387	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-42.54	-519,000	217,000	-%
2023-05-18	JPMORGAN CHASE & CO	added	0.35	-3,264,000	3,472,000	-%
2023-05-16	JANE STREET GROUP, LLC	new	-	1,435,660	1,435,660	-%
2023-05-16	PERCEPTIVE ADVISORS LLC	sold off	-100	-5,374,510	-	-%
2023-05-16	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	230,371	230,371	-%
2023-05-15	Weiss Multi-Strategy Advisers LLC	new	-	477,000	477,000	0.01%
2023-05-15	SAMLYN CAPITAL, LLC	new	-	8,507,190	8,507,190	0.15%
2023-05-15	TWO SIGMA ADVISERS, LP	new	-	327,645	327,645	-%

Latest Funds Activity

Are funds buying ACRS calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ACRS

No. of Funds

Aclaris Therapeutics News

Schedule 13G FIlings of Aclaris Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2023	wellington management group llp	11.05%	7,372,601	SC 13G/A
Mar 16, 2023	biotechnology value fund l p	2.7%	1,794,881	SC 13G
Feb 14, 2023	rock springs capital management lp	5.94%	3,961,249	SC 13G/A
Feb 14, 2023	biotechnology value fund l p	2.6%	1,732,725	SC 13G/A
Feb 13, 2023	foresite capital fund iv, l.p.	4.2%	2,808,034	SC 13G/A
Feb 06, 2023	wellington management group llp	8.22%	5,484,013	SC 13G/A
Jan 31, 2023	blackrock inc.	7.6%	5,087,435	SC 13G/A
Apr 25, 2022	ra capital management, l.p.	7.1%	4,398,453	SC 13G
Feb 15, 2022	rock springs capital management lp	6.31%	3,861,347	SC 13G/A
Feb 14, 2022	venrock healthcare capital partners ii, l.p.	7.5%	4,563,962	SC 13G

ACRS Fair Value

Show Fair-Value

Recent SEC filings of Aclaris Therapeutics

View All Filings

Date Filed	Form Type	Document
Jun 02, 2023	8-K	Current Report
Jun 01, 2023	8-K	Current Report
May 08, 2023	10-Q	Quarterly Report
May 08, 2023	8-K	Current Report
May 08, 2023	S-8	Employee Benefits Plan
Apr 20, 2023	ARS	ARS
Apr 20, 2023	DEF 14A	DEF 14A
Apr 20, 2023	DEFA14A	DEFA14A
Apr 14, 2023	8-K	Current Report
Apr 10, 2023	PRE 14A	PRE 14A

Latest Insider Trading transactions for ACRS

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-17	Manion Douglas J.	bought	49,532	7.8623	6,300	pres and ceo
2023-03-09	Manion Douglas J.	bought	50,277	7.735	6,500	pres and ceo
2023-03-03	Monahan Joseph	sold	-202,615	12.6342	-16,037	chief scientific officer
2023-03-03	Balthaser Kevin	sold	-11,289	12.6281	-894	chief financial officer
2023-03-03	Walker Neal	sold	-382,070	12.6346	-30,240	-
2023-03-02	Walker Neal	acquired	-	-	18,254	-
2023-03-02	Balthaser Kevin	sold	-12,289	12.289	-1,000	chief financial officer
2023-03-02	Monahan Joseph	sold	-183,024	12.3665	-14,800	chief scientific officer
2023-03-02	Balthaser Kevin	acquired	-	-	1,500	chief financial officer
2023-03-02	Walker Neal	sold	-358,588	12.3651	-29,000	-

About Aclaris Therapeutics

Neal S. Walker

www.aclaristx.com

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

ACRS Income Statement

2023-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Total revenue	$ 2,528	$ 1,453
Costs and expenses:
Cost of revenue	808	1,155
Research and development	22,587	14,306
General and administrative	8,790	6,099
Licensing	1,061
Revaluation of contingent consideration	(800)	(1,200)
Total costs and expenses	32,446	20,360
Loss from operations	(29,918)	(18,907)
Other income, net	1,758	118
Net loss	$ (28,160)	$ (18,789)
Net loss per share, basic	$ (0.42)	$ (0.31)
Net loss per share, diluted	$ (0.42)	$ (0.31)
Weighted average common shares outstanding, basic	66,872,778	61,431,026
Weighted average common shares outstanding, diluted	66,872,778	61,431,026
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities, net of tax of $0	$ 543	$ (748)
Total other comprehensive income (loss)	543	(748)
Comprehensive loss	(27,617)	(19,537)
Contract research
Revenues:
Total revenue	889	1,221
Licensing
Revenues:
Total revenue	$ 1,639	202
Other
Revenues:
Total revenue		$ 30

ACRS Balance Sheet

2023-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 44,722	$ 45,277
Short-term marketable securities	126,081	172,294
Accounts receivable, net	686	484
Prepaid expenses and other current assets	12,872	13,495
Total current assets	184,361	231,550
Marketable securities	33,602	12,242
Property and equipment, net	1,513	1,099
Intangible assets	6,954	6,973
Other assets	3,275	2,732
Total assets	229,705	254,596
Current liabilities:
Accounts payable	8,190	10,351
Accrued expenses	7,263	8,701
Current portion of lease liabilities	603	684
Discontinued operations	2,202	2,202
Total current liabilities	18,258	21,938
Other liabilities	1,970	1,570
Contingent consideration	32,300	33,100
Deferred tax liability	367	367
Total liabilities	52,895	56,975
Commitments and contingencies (Note 14)
Stockholders' Equity:
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at March 31, 2023 and December 31, 2022
Common stock, $0.00001 par value; 100,000,000 shares authorized at March 31, 2023 and December 31, 2022; 67,206,025 and 66,688,647 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	1	1
Additional paidin capital	887,638	880,832
Accumulated other comprehensive loss	(354)	(897)
Accumulated deficit	(710,475)	(682,315)
Total stockholders' equity	176,810	197,621
Total liabilities and stockholders' equity	$ 229,705	$ 254,596